What is the share price of Sanofi India Ltd (SANOFI) today?
The share price of SANOFI as on 5th December 2025 is ₹4330.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sanofi India Ltd (SANOFI) share?
The past returns of Sanofi India Ltd (SANOFI) share are- Past 1 week: -0.12%
- Past 1 month: -7.94%
- Past 3 months: -14.94%
- Past 6 months: -29.87%
- Past 1 year: -31.07%
- Past 3 years: -24.18%
- Past 5 years: -46.01%
What are the peers or stocks similar to Sanofi India Ltd (SANOFI)?
The peers or stocks similar to Sanofi India Ltd (SANOFI) include:What is the dividend yield % of Sanofi India Ltd (SANOFI) share?
The current dividend yield of Sanofi India Ltd (SANOFI) is 2.70.What is the market cap of Sanofi India Ltd (SANOFI) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanofi India Ltd (SANOFI) is ₹9972.72 Cr as of 5th December 2025.What is the 52 week high and low of Sanofi India Ltd (SANOFI) share?
The 52-week high of Sanofi India Ltd (SANOFI) is ₹6717 and the 52-week low is ₹4305.What is the PE and PB ratio of Sanofi India Ltd (SANOFI) stock?
The P/E (price-to-earnings) ratio of Sanofi India Ltd (SANOFI) is 24.13. The P/B (price-to-book) ratio is 11.59.Which sector does Sanofi India Ltd (SANOFI) belong to?
Sanofi India Ltd (SANOFI) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sanofi India Ltd (SANOFI) shares?
You can directly buy Sanofi India Ltd (SANOFI) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sanofi India Ltd
SANOFI Share Price
4,330.200.97% (-42.60)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SANOFI Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SANOFI Performance & Key Metrics
SANOFI Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 27.99 | 11.59 | 2.70% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
100%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
SANOFI Company Profile
Sanofi India Limited is engaged in the manufacture and sale of pharmaceutical products.
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
SANOFI Sentiment Analysis
SANOFI Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SANOFI Stock Summary · November 2025
Sanofi India Limited is undergoing a transformative phase, focusing on enhancing its leadership in the insulin market through a customer-centric and digitally empowered approach. This strategy has led to a notable 4% year-to-date growth in its diabetes insulin segment, despite challenges such as declining export revenues due to divestments and regulatory delays. The company is prioritizing existing products like Toujeo and Soliqua while adopting a cautious stance on new launches, ensuring alignment with market needs and operational efficiency. Partnerships are enhancing market access, particularly in Tier 2 and Tier 3 cities, while AI integration is improving forecasting and inventory management. Overall, the sentiment remains positive, with expectations for continued growth in both revenue and profitability.
SANOFI Stock Growth Drivers
SANOFI Stock Growth Drivers
6Transformation and Modernization
Sanofi India Limited has undergone a significant transformation aimed at strengthening its leadership in the
Financial Performance and Cost Management
The company has reported a significant reduction in operational expenses (OPEX), down 30% compared to
SANOFI Stock Challenges
SANOFI Stock Challenges
4Export Revenue Decline
The company has experienced a significant decline in export revenues, which account for approximately 12%
Operational Challenges and Cost Management
The company has faced operational challenges, particularly in managing costs associated with personnel and operating
SANOFI Forecast
SANOFI Forecasts
Price
Revenue
Earnings
SANOFI Share Price Forecast
SANOFI Share Price Forecast
2025
Current
₹4,330.20
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹4,330.20
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
SANOFI Company Revenue Forecast
SANOFI Company Revenue Forecast
2024
Current
₹2.13
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2024
Current
₹2.13
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
SANOFI Stock EPS (Earnings Per Share) Forecast
SANOFI Stock EPS (Earnings Per Share) Forecast
2024
Current
₹179.46
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹179.46
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
SANOFI
SANOFI
Income
Balance Sheet
Cash Flow
Annual Normal View
SANOFI Income Statement
SANOFI Income Statement
Annual Normal View
| Financial Year | FY 2023 | FY 2024 | TTM | |||
|---|---|---|---|---|---|---|
| Total Revenue | 2,313.40 | 2,129.30 | 1,963.30 | |||
Raw Materials | 1,237.20 | 919.10 | 1,440.50 | |||
| Power & Fuel Cost | 8.40 | 11.60 | ||||
| Employee Cost | 280.70 | 240.20 | ||||
| Selling & Administrative Expenses | 192.70 | 212.10 | ||||
| Operating & Other expenses | -210.60 | 177.10 | ||||
EBITDA | 805.00 | 569.20 | 522.80 | |||
| Depreciation/Amortization | 36.50 | 36.70 | 37.40 | |||
| PBIT | 768.50 | 532.50 | 485.40 | |||
| Interest & Other Items | 1.70 | 1.50 | 1.50 | |||
| PBT | 766.80 | 531.00 | 483.90 | |||
| Taxes & Other Items | 163.90 | 117.70 | 127.60 | |||
| Net Income | 602.90 | 413.30 | 356.30 | |||
| EPS | 261.78 | 179.46 | 154.71 | |||
| DPS | 167.00 | 117.00 | 117.00 | |||
| Payout ratio | 0.64 | 0.65 | 0.76 |
SANOFI Company Updates
FY 2026FY 2026
Investor Presentation
Oct 29PDF
FY 2025FY 2025
SANOFI Stock Peers
SANOFI Past Performance & Peer Comparison
SANOFI Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sanofi India Ltd | 24.13 | 11.59 | 2.70% |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
SANOFI Stock Price Comparison
Compare SANOFI with any stock or ETFCompare SANOFI with any stock or ETF
SANOFI
SANOFI Holdings
SANOFI Shareholdings
SANOFI Promoter Holdings Trend
SANOFI Promoter Holdings Trend
SANOFI Institutional Holdings Trend
SANOFI Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SANOFI Shareholding Pattern
SANOFI Shareholding Pattern
SANOFI Shareholding History
SANOFI Shareholding History
Foreign Institutions
Mutual Funds Invested in SANOFI
Mutual Funds Invested in SANOFI
No mutual funds holding trends are available
Top 5 Mutual Funds holding Sanofi India Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2060% | Percentage of the fund’s portfolio invested in the stock 0.24% | Change in the portfolio weight of the stock over the last 3 months -0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 79/101 (-14) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2002% | Percentage of the fund’s portfolio invested in the stock 0.39% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 53/100 (-20) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1992% | Percentage of the fund’s portfolio invested in the stock 0.52% | Change in the portfolio weight of the stock over the last 3 months -0.46% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 28/69 (0) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing SANOFI stock
smallcases containing SANOFI stock
Looks like this stock is not in any smallcase yet.
SANOFI Events
SANOFI Events
SANOFI Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SANOFI Dividend Trend
No dividend trend available
SANOFI Upcoming Dividends
SANOFI Upcoming Dividends
No upcoming dividends are available
SANOFI Past Dividends
SANOFI Past Dividends
Cash Dividend
Ex DateEx DateNov 7, 2025
Interim
Interim | Div/Share: ₹75.00
Dividend/Share
₹75.00
Ex DateEx Date
Nov 7, 2025
Cash Dividend
Ex DateEx DateApr 25, 2025
Final
Final | Div/Share: ₹117.00
Dividend/Share
₹117.00
Ex DateEx Date
Apr 25, 2025
Cash Dividend
Ex DateEx DateMay 3, 2024
Final
Final | Div/Share: ₹117.00
Dividend/Share
₹117.00
Ex DateEx Date
May 3, 2024
Cash Dividend
Ex DateEx DateMar 7, 2024
Interim
Interim | Div/Share: ₹50.00
Dividend/Share
₹50.00
Ex DateEx Date
Mar 7, 2024
Cash Dividend
Ex DateEx DateApr 28, 2023
Final
Final | Div/Share: ₹194.00
Dividend/Share
₹194.00
Ex DateEx Date
Apr 28, 2023
SANOFI Stock News & Opinions
SANOFI Stock News & Opinions
Articles & Videos
Earnings
Sanofi India standalone net profit declines 7.54% in the September 2025 quarter
Net profit of Sanofi India declined 7.54% to Rs 76.00 crore in the quarter ended September 2025 as against Rs 82.20 crore during the previous quarter ended September 2024. Sales declined 9.27% to Rs 475.40 crore in the quarter ended September 2025 as against Rs 524.00 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales475.40524.00 -9 OPM %28.2322.84 - PBDT138.70121.60 14 PBT129.60112.60 15 NP76.0082.20 -8 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Sanofi India recommends Interim Dividend
Sanofi India announced that the Board of Directors of the Company at its meeting held on 29 October 2025, has recommended a Interim Dividend of Rs.75 per share (i.e.750%), subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Sanofi India approves change in directorate
The Board of Sanofi India at its meeting held on 27 October 2025 has approved the following- Appointment of Deepak Arora (DIN: 07495638) as an Additional Director of the Company with effect from 27 October 2025 and as a Managing Director (Key Managerial Personnel) of the Company for a term of 3 (three) years effective from 27 October 2025. Stepping down of Rachid Ayari as Interim Managing Director of the Company with effect from close of 26 October 2025. However, Rachid Ayari would continue to serve the Company in his role as Whole time Director and Chief Financial Officer of the Company.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Sanofi India to table results
Sanofi India will hold a meeting of the Board of Directors of the Company on 29 October 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Sanofi India announces cessation of senior management personnel
Sanofi India announced that Surabhi Kaul, People Director - SEA&I, will cease to be a Senior Management Personnel (SMP) of the Company effective from the close of business on 14 August 2025, in view of her movement to another role within the Sanofi group. Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Sanofi India standalone net profit declines 32.79% in the June 2025 quarter
Net profit of Sanofi India declined 32.79% to Rs 69.50 crore in the quarter ended June 2025 as against Rs 103.40 crore during the previous quarter ended June 2024. Sales declined 12.34% to Rs 406.30 crore in the quarter ended June 2025 as against Rs 463.50 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales406.30463.50 -12 OPM %23.3624.96 - PBDT103.20120.10 -14 PBT94.10111.10 -15 NP69.50103.40 -33 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Sanofi India to hold board meeting
Sanofi India will hold a meeting of the Board of Directors of the Company on 31 July 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Sanofi India consolidated net profit declines 12.52% in the March 2025 quarter
Net profit of Sanofi India declined 12.52% to Rs 119.50 crore in the quarter ended March 2025 as against Rs 136.60 crore during the previous quarter ended March 2024. Sales rose 4.91% to Rs 535.90 crore in the quarter ended March 2025 as against Rs 510.80 crore during the previous quarter ended March 2024. ParticularsQuarter EndedMar. 2025Mar. 2024% Var. Sales535.90510.80 5 OPM %32.0826.84 - PBDT174.90140.30 25 PBT165.30131.20 26 NP119.50136.60 -13 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Sanofi India to hold board meeting
Sanofi India will hold a meeting of the Board of Directors of the Company on 14 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Spotlight
Sanofi India MD Rodolfo Hrosz resigns
The board of directors accepted Hrosz's resignation during a meeting held on 9 April and expressed appreciation for his significant contributions during his tenure. Hrosz will cease to be a key managerial personnel, senior management personnel, and a member of board committees at the close of business hours on 30 April 2025. Further, the board approved Hrosz's appointment as an additional non-executive director effective 1 May 2025, subject to shareholder approval, upon the recommendation of the nomination and remuneration committee (NRC). Sanofi India is among the leading multinational companies in the Indian pharmaceutical market. It offers a wide array of medicines for therapy areas such as diabetes, cardiology, thrombosis, the central nervous system, and antihistamines. The company's consolidated net profit declined 33.7% to Rs 91.30 crore in Q4 FY25 as against Rs 137.70 crore reported in Q4 FY24. Total revenue from operations grew by 9.7% year on year (YoY) to Rs 514.90 crore in the quarter ended 31 March 2024. Shares of Sanofi India rose 0.83% to Rs 6,100 on the BSE. Powered by Capital Market - Live
7 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant